Navigation Links
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Date:6/1/2008

CHICAGO, June 1 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced positive results from its Phase II clinical trial of OncoVEX GM-CSF, an oncolytic for the treatment of advanced metastatic melanoma, at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Clinical Trial Details

Phase II Trial Design: The Phase II trial was conducted at seven U.S. clinical centers, including the Mary Crowley Cancer Research Center, Dallas, TX; Columbia University, New York, NY; The Hubert H. Humphrey Cancer Center, Minneapolis, MN; and the University of California San Diego, San Diego, CA. Fifty patients with inoperable Stage IIIc/IV melanoma were enrolled. Patients were given OncoVEX GM-CSF injections every two weeks for up to a year. The trial was designed to measure overall objective response, which is defined as a complete response, where disease is completely eliminated, or partial response, where there is a >30% reduction in disease burden. The target efficacy endpoint detailed in the Phase II protocol and agreed with the FDA was to achieve two objective responses or stable disease >2 months.

Phase II results: Among 43 patients currently evaluable of the 50 patients enrolled, tumors injected with OncoVEX GM-CSF routinely responded, often with local complete responses or palliative benefit. With regard to systemic overall responses required for treatment success (including tumor responses at sites distant from injected tumors), six patients showed complete clinical responses; five of which are ongoing at between four and 27 months post first injection. The sixth complete response patient presented with a new lesion 15 months after initiating therapy. A further six patients achieved a partial response, five of which are ongoing 7-13 months post first injection and two of which have no disease after surgical r
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
2. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
3. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
4. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
5. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Neurocrine Biosciences Reports First Quarter 2008 Results
10. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
11. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... by the collapse of one or more vertebral ... patients. Osteoporosis, a degenerative bone disease, is a ... bone disease, multiple myeloma, metastatic spinal tumors, and ... can undergo vertebroplasty and kyphoplasty to rectify the ...
(Date:9/2/2015)... Sept. 2, 2015  The report on breast cancer ... breast cancer drugs on the basis of the molecules ... from the inner lining of milk ducts or lobules ... type of tumor that can spread to other cells ... starts in lobules is referred as lobular carcinoma, while ...
(Date:9/2/2015)... -- About Neuroendovascular Coil A ... and ruptured brain aneurysm (a weakened area in ... as an endovascular coiling or endovascular embolization. During ... flow in an aneurysm. The endovascular coiling treatment ... interventional neuroradiologist using fluoroscopic imaging guidance. Neuroendovascular coils ...
Breaking Medicine Technology:Global Balloon Kyphoplasty Market 2015-2019 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Neuroendovascular Coil Market 2015-2019 2
... VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ), a biotechnology ... treatment of cardiovascular disease, announced today that,it will ... results of the,VIA-2291 Phase 2 acute coronary syndrome ... American Heart Association (AHA) Scientific,Sessions 2008 on Sunday, ...
... Nov. 5 Medarex, Inc.,(Nasdaq: MEDX ) ... payment of,an undisclosed amount from its licensing partner, ... 2 trial of CNTO 95, a fully human ... tumor-induced,angiogenesis. The CNTO 95 human antibody was generated ...
Cached Medicine Technology:VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA 2Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors 2
(Date:9/3/2015)... ... ... is an unavoidable result of incision or injury to the skin. Unsightly as it may ... appearance of a scar is dependent on many factors – the size and depth of ... to near invisibility on their own over a period of months,” says Dr. Jocelyn ...
(Date:9/3/2015)... ... , ... “Love in Tokyo” an independent romantic comedy film by Michael Solton ... and will be released on DVD early next year, by Maverick Entertainment. The film ... and singer/songwriter, and Jason London, lead from “Dazed and Confused.” , “Love in ...
(Date:9/3/2015)... ... 2015 , ... Representatives with State Farm Agent EJ Roberts ... Gulf Babypalooza on September 19, 2015. , “We will be providing information to ... We will be discussing setting up college funds, offering information specific to their ...
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we have seen ... traditional health care model, where the primary care physician dictates and the patient obeys. ... become educated about their health issues and empowered to choose their own treatment options. ...
(Date:9/3/2015)... ... 03, 2015 , ... About 220,800 new cases of prostate cancer are reported each year, along ... with prostate cancer during their lifetime. While only one man in 10,000 will typically get ... age 65, according to the American Cancer Society. , Prostate cancer ...
Breaking Medicine News(10 mins):Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
... Care Physician Recruitment, ORLANDO, Fla., Nov. 10 ... - with primary care,being especially hard hit. As the ... shortage promises to get worse with major,repercussions for the ... working to address this issue with a new policy ...
... - BELLUS Health Inc. (NASDAQ:,BLUS; TSX: BLU) reports ... For the three-month period ended September 30, 2008, ... compared to $13,889,000 ($0.29,per share) for the corresponding ... September 30, 2008, the net loss amounted to,$36,703,000 ...
... Adds Fuel to Double-Digit Growth in Europe, PROVO, ... (NYSE: NUS ) opened for business in the ... adds further fuel to the,company,s increasingly successful European region., ... the,Czech Republic is becoming a dynamic market for direct ...
... 10 Medipacs, Inc., a Tucson based,drug delivery ... and Agustin Vilches, RPh to the company,s medical ... and together have practiced,in Hospital, Hospice and Home ... years at Swedish Hospital Medical,Center and the Fred ...
... and Address Vital Breast Cancer Health ... Care Issues for All Illinois Residents, SPRINGFIELD, Ill., Nov. 10 ... of the global breast cancer movement,will convene at the first-ever Komen ... state,s breast health coverage, discuss,the impact of statewide breast health programs ...
... Nov. 10 Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... results on November 13, 2008, before the open,of U.S. ... and live audio webcast to discuss the results and ... Time/5:30 a.m. Pacific,Time., The live webcast and press ...
Cached Medicine News:Health News:AMA Works to Reverse Primary Care Physician Shortage 2Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 2Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 3Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 4Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 5Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 6Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 7Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 8Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 9Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 10Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 11Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 12Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 13Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 14Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 15Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 16Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 17Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 18Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 19Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 20Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 21Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 22Health News:BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update 23Health News:Nu Skin Enterprises Opens the Czech Republic 2Health News:Medipacs Appoints Advisory Board Members 2Health News:Susan G. Komen for the Cure(R) Hosts Inaugural Illinois State Summit in Springfield 2Health News:Jazz Pharmaceuticals, Inc. to Announce Third Quarter Financial Results on November 13, 2008 2
Indicated for procedures of the wrist, ankle, elbow, and other small joints, the,UltrAblator is effective for ablation of soft tissue and coagulation of bleeders,encountered during surgery....
... is designed to replace the carpal scaphoid bone. ... pole which fits under a shelf formed in ... suture hole on the proximal hole for suture ... the early postoperative period until a firm capsuloligamentous ...
... has the same anatomical configuration as the ... to provide for stability. The implant has ... use in suture fixation through the scaphoid ... while a capsuloligamentous system forms around the ...
... The Diamond plate is designed for ... lunate and triquetrum bones in the hand. ... patients suffering from pain and/or loss of ... post-traumatic arthritis, fractures, carpal instability or rheumatoid ...
Medicine Products: